# Role of Nebulized Dexmedetomidine in Blunting the Effects of Direct Laryngoscopy and Endotracheal Tube on Heart Rate and Blood Pressure.

> **NCT06103721** · PHASE4 · UNKNOWN · sponsor: **Muhammad Haroon Anwar** · enrollment: 126 (estimated)

## Conditions studied

- Hemodynamic Instability

## Interventions

- **DRUG:** Dexmedetomidine Injection [Precedex]
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT06103721
- **Lead sponsor:** Muhammad Haroon Anwar
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-21
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2023-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06103721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06103721, "Role of Nebulized Dexmedetomidine in Blunting the Effects of Direct Laryngoscopy and Endotracheal Tube on Heart Rate and Blood Pressure.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06103721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*